Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HRH2 | P25021 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL124103 | 0.93 | L3MBTL1 (0.55) | L3MBTL1ATMMEN1KMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL2858521 | 0.91 | L3MBTL1 (0.54) | L3MBTL1ATMMEN1KMT2AKDM4E | |
| SCHEMBL5640211 | 0.88 | HRH2 (0.56) | KDM4EALDH1A1HRH2 | |
| SCHEMBL11147455 | 0.86 | MEN1 (0.55) | L3MBTL1ATMMEN1KMT2AKDM4E | |
| SCHEMBL4937902 | 0.85 | MEN1 (0.71) | L3MBTL1ATMMEN1KMT2AKDM4E | |
| SCHEMBL1904635 | 0.85 | MEN1 (0.71) | L3MBTL1ATMMEN1KMT2AKDM4E | |
| SCHEMBL1188654 | 0.85 | MEN1 (0.71) | L3MBTL1ATMMEN1KMT2AKDM4E | |
| SCHEMBL1627052 | 0.84 | MEN1 (0.77) | L3MBTL1ATMMEN1KMT2AKDM4E | |
| SCHEMBL8319572 | 0.83 | AGTR2 (0.55) | KDM4EALDH1A1HRH2 | |
| SCHEMBL9581725 | 0.82 | L3MBTL1 (0.55) | L3MBTL1ATMKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2934533-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2017-11-15 | — | — | EP | disclosed |
| US-9573961-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20150329557-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME CORP. (US) | 2015-11-19 | — | — | US | disclosed |
| EP-2934533-A2 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014099633-A2 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2014-06-26 | — | — | WO | disclosed |
| US-7795267-B2 | Bicyclic piperazine compound having TGR23 antagonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| EP-1661898-A1 | BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329557-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | KCNJ11, KCNJ1, KCNJ2 | L3MBTL1 3556/4885ATM 3781/4885MEN1 324/4885 |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | GPR3, FFAR3, LPAR3 | L3MBTL1 2503/4885ATM 3450/4885MEN1 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.